Palvella Therapeutics (PVLA) Cash & Current Investments (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Cash & Current Investments data on file, last reported at $261.9 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 246.25% year-over-year to $261.9 million in Q1 2026; TTM through Mar 2026 was $261.9 million, a 246.25% increase from a year earlier, with the FY2025 full-year figure at $58.0 million, down 30.65% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $261.9 million, up from $58.0 million in the prior quarter.
• Over the last five years, Cash & Current Investments for PVLA reached as high as $261.9 million in Q1 2026 and fell as low as $6.2 million in Q1 2024.
• Historically, Cash & Current Investments has averaged $69.1 million across 5 years, with a median of $63.6 million in 2025.
• Across the five-year window, Cash & Current Investments tumbled 89.05% in 2024 and surged 1110.4% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $59.2 million in 2022, then sank by 72.42% to $16.3 million in 2023, then jumped by 412.27% to $83.6 million in 2024, then slumped by 30.65% to $58.0 million in 2025, then jumped by 351.61% to $261.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $261.9 million in Q1 2026, $58.0 million in Q4 2025, and $63.6 million in Q3 2025.